Notice of Interim Results
Oxford, UK – 3 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, will be announcing its interim results for the six months ended 30 June 2014 on Tuesday 29 July 2014.
An analyst meeting will take place at 9.30am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD, with registration and coffee from 9.15am BST. A webcast of the event will be available in the Media section of the Company’s website at www.circassia.com.
For further information, please contact:
Steve Harris, Chief Executive Officer
Julien Cotta, Chief Financial Officer
Lara Flynn, Vice President Corporate Affairs
Tel: +44 (0)1865 405 560
J.P. Morgan Cazenove
Gina Gibson / Siddharth Natarajan
Tel: +44 (0) 20 7742 4000
James Steel / Clare Terlouw
Tel: +44 (0) 20 7418 8900
Ben Atwell / John Dineen
Tel: +44 (0) 20 3727 1000
Notes to editors
Circassia is a specialty biopharmaceutical company focused on the development and commercialisation of a range of immunotherapy product candidates for the treatment of allergy. Established in 2006, the Company has used its innovative proprietary technology, ToleroMune® to develop a new class of allergy therapies, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs), which Circassia believes represents a step change to a new generation of allergy treatment. The Company’s portfolio of product candidates is designed to treat a broad range of seasonal and perennial allergies. The lead product candidate Cat-SPIRE, a new treatment for cat allergy, is currently in phase III development and three other product candidates have completed phase IIb clinical studies. As Circassia continues to grow, the Company remains focused on its founding principle – a commitment to improving patients’ lives by controlling immune responses. Further information is available at: www.circassia.com.